期刊
BIOSENSORS & BIOELECTRONICS
卷 195, 期 -, 页码 -出版社
ELSEVIER ADVANCED TECHNOLOGY
DOI: 10.1016/j.bios.2021.113646
关键词
CRISPR-Cas12a; Gold nanoparticles; SARS-CoV-2 detection; Smartphone-based diagnostics; Visual biosensor; Clinical samples
类别
资金
- National Natural Science Foundation of China [32072309, 21672161, 81503086]
- Tianjin Municipal Science and Technology Committee [19JCYBJC27800]
- State Key Laboratory of Food Nutrition and Safety, Tianjin University of Science Technology [19PTSYJC00060]
Researchers have developed a CRISPR-Cas12a powered biosensor for ultra-sensitive and selective detection of SARS-CoV-2, with smartphone readout capability. The biosensor showed excellent performance in detecting synthetic vectors, transcribed RNA, and pseudoviruses, providing 100% agreement with qPCR results when tested with clinical samples. It offers a novel and robust technology for clinically sensitive detection of SARS-CoV-2.
The pandemic of coronavirus disease 2019 (COVID-19) resulted from novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a worldwide concern. It is imperative to develop rapid, sensitive, and specific biosensing methods. Herein, we developed a CRISPR-Cas12a powered visual biosensor with a smart phone readout for ultrasensitive and selective detection of SARS-CoV-2. Simply, the SARS-CoV-2 derived nucleic acids triggered CRISPR-Cas12a based indiscriminate degradation of a single-stranded DNA that was supposed to link two gold nanoparticles, inducing the dis-aggregation of gold nanoparticles and thus generating observable color changes. This change can be readily distinguished by naked eyes as well as a smartphone with a Color Picker App. The proposed biosensor was successfully applied to detect SARS-CoV-2 gene in synthetic vectors, transcribed RNA and SARS-CoV-2 pseudoviruses. It rendered single copy resolution as evidenced by the 1 copy/mu L limit of detection of pseudoviruses with no cross-reactivity. When the developed biosensor was challenged with SARS-CoV-2 clinical bio-samples, it provided 100% agreement (both positive and negative) with qPCR results. The sample-to-result time was roughly 90 min. Our work provides a novel and robust technology for ultrasensitive detection of SARS-CoV-2 that could be used clinically.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据